William Blair Maintains Their Buy Rating on Retrophin (RTRX)

By Ryan Adsit

In a report released yesterday, Tim Lugo from William Blair maintained a Buy rating on Retrophin (RTRXResearch Report). The company’s shares closed last Monday at $13.93, close to its 52-week low of $11.84.

According to TipRanks.com, Lugo is a 4-star analyst with an average return of 9.7% and a 37.8% success rate. Lugo covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, BioMarin Pharmaceutical Inc., and Aclaris Therapeutics Inc.

Retrophin has an analyst consensus of Strong Buy, with a price target consensus of $31.50, implying a 131.6% upside from current levels. In a report issued on August 7, Canaccord Genuity also maintained a Buy rating on the stock with a $38 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $33 and a one-year low of $11.84. Currently, Retrophin has an average volume of 581.8K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Retrophin, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.